Is GH or IMDX more undervalued in 2026?

CirclFi compares Guardant Health, Inc. (GH) and Insight Molecular Diagnostics I (IMDX) using 13 institutional-grade valuation models. GH has a Quality of Company score of 6.7/10 while IMDX scores 5.3/10.

Which is a better buy — GH or IMDX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GH and IMDX valuations compare?

GH at $133.22 and IMDX at $6.53 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GH vs IMDX Valuation Comparison 2026 — Intrinsic Value Analysis

GH

Diagnostics & Research

Guardant Health, Inc.

Quality

6.7

out of 10

Value Trap

SAFE

Price

$133.22

Last close

Models

11/13

Active

IMDX

Diagnostics & Research

Insight Molecular Diagnostics I

Quality

5.3

out of 10

Value Trap

SAFE

Price

$6.53

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	GH Fair Value	GH Upside	IMDX Fair Value	IMDX Upside
Bayesian DCF	Intrinsic	$40.57	-69.5%	$2.19	-66.5%
Earnings Power Value	Intrinsic	$11.59	-86.8%	$1.19	-71.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GH vs IMDX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GH vs IMDX — Which Stock Is More Undervalued?

GH scores higher with a 6.7/10 quality rating vs IMDX's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Guardant Health, Inc. (GH) and Insight Molecular Diagnostics I (IMDX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GH currently trades at $133.22 with a QOC of 6.7/10, while IMDX trades at $6.53 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).